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Purpose	We investigated factors driving health care costs of patients with a diagnosis of acute myeloid and
acute lymphoblastic leukemia.
Methods

 tandard costs identified in insurance claims data obtained from the Wisconsin Health Information
S
Organization were used in a sample of 837 acute leukemia patients from April 2009 to June 2011. The
Andersen behavioral model of health care utilization guided selection of patient and community factors
expected to influence health care costs. A generalized linear model fitting gamma-distributed data with
log-link technique was used to analyze cost.

Results

 ype of treatment received and disease severity represented significant cost drivers, and patients
T
receiving at least some of their treatment from academic medical centers experienced higher costs.
Inpatient care and pharmacy costs of patients who received treatment from providers located in areas
of higher poverty experienced lower costs, raising questions of potential treatment and medical practice
disparities between provider locations. Directions of study findings were not consistent between
different types of services received and underscore the complexity of investigating health care cost.

Conclusions	While prevalence of acute leukemia in the United States is low compared to other diseases, its extreme
high cost of treatment is not well understood and potentially influences treatment decisions. Acute
leukemia health care costs may not follow expected patterns; further exploration of the relationship
between cost and the treatment decision, and potential treatment disparities between providers in
different socioeconomic locations, is needed. (J Patient Cent Res Rev. 2016;3:142-149.)
Keywords	health care costs; acute leukemia cost; administrative data use

As the United States health care system works to control
health care costs, it becomes increasingly important to
understand the factors associated with high-cost care.1
Exploring cost factors of low-prevalence but highcost cancers is important to both identify and better
understand underlying health care utilization patterns
and cost. In 2007, Yu found the use of prolonged
hospital care, high levels of medical technology and
specialized health care services resulted in a high cost
of treatment.2 To achieve long-term survival, patients
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diagnosed with acute leukemia are expected to utilize
diverse health care services.
Prior models of health care utilization have identified
patient and community factors as determinants in the
use of services.3-5 Specifically, the Andersen behavioral
model proposes that an individual’s health care use
can be attributed to individual and community or
organizational factors that will either increase or
decrease utilization.4 Utilization factors are associated
with biology (such as age and gender), social structure
(such as education, occupation, ethnicity, environment
and culture), and health beliefs (such as attitudes,
values and knowledge). Furthermore, the availability
of individual and community resources like income,
insurance, transportation and diversity of services
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offered drive the use of health care. Finally, utilization
may be influenced by the individual’s perceived or
evaluated need for these services as well as his or her
ability to access health care resources, work within the
health care system and effectively manage the clinical
problem. Understanding cost factors of uncommon,
high-cost cancers is important to patients, providers
and communities impacted by these diseases.
This study investigated patient and community
variables that may influence the cost of treatment for
patients in Wisconsin diagnoses with acute myeloid
leukemia or acute lymphoblastic leukemia. More
specifically, this study sought to identify factors that
may influence higher cost treatment of these two
diseases.

METHODS

Data Source and Study Population
This study received approval from the University of
Wisconsin-Milwaukee Institutional Review Board.
Insurance claims data obtained from the Wisconsin
Health Information Organization (WHIO) Datamart
were used to identify a study population of 837 acute
leukemia patients treated with chemotherapy alone or
chemotherapy and hematopoietic stem cell transplant
(HCT) from April 2009 to June 2011. WHIO is a
statewide collaboration of insurance companies, health
care providers, large employers and public agencies.
Starting in 2005, this group developed a state-level
database of health insurance claims in order to provide
data useful for examining health care issues related
to quality, efficiency and safety within the state of
Wisconsin.6 Access to the data is available through
the WHIO Health Analytics Exchange, a database
reporting system covering more than 247.6 million
insurance claims for care to roughly 3.8 million
Wisconsin residents. The exchange began collecting
data in 2008 and provides access to a rolling 27
months of data, a total of 23.1 million episodes of care.
Version 6 of the WHIO Datamart contains information
for approximately 64.9% of Wisconsin’s population.
Commercial claims represent 42% of the total, 25% are
Medicaid Fee-For-Service claims, 20% are Medicaid
HMO claims, and 13% are Medicare claims. The active
WHIO Datamart contains 24 months of insurance
claims data collected over 27 months for completeness
and refreshed approximately every 6 months.6
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The study population included all patients with an
ICD-9 diagnosis code of acute myeloid leukemia or
acute lymphoblastic leukemia present in the WHIO
database within the 2009–2011 timeframe. Claims
costs were categorized and are presented as billed
cost, paid cost and standard cost; standard cost is
used in these analyses. Finkler previously identified
the appropriate use of standard cost for studies with
the perspective of actual operational cost or resources
used.7 WHIO calculates a standard cost variable to
adjust for variations related to insurance contracting,
region and disease severity and comorbidity, which is
expected to provide a closer estimate of actual cost.
Design and Variables
This study is a cross-sectional secondary analysis of
insurance claims data from the WHIO Datamart for
patients with acute leukemia. With guidance from
the Andersen model, study variables (Table 1) were
included based on their expected influence on health
care cost at the patient and community level.
Patient county and provider location percentage
below poverty variables were calculated using
WHIO data combined with U.S. Census data. Six
cost criterion variables were analyzed separately:
1) total cost, 2) ancillary cost, 3) inpatient cost, 4)
outpatient cost, 5) pharmacy cost, and 6) professional
cost. Data were not consistently available for each
cost criterion; therefore, while the total cost data set
included all 837 patients, each analysis utilized only
the data and corresponding population size available
per cost criterion.
Statistical Analyses
Use of administrative databases in health care
cost research is challenging due to the limitations
of patient demographics, disruption in coverage,
availability of clinical outcomes and censored data.
Using prior literature as a guide, a generalized
linear model (GLM) fitting gamma-distributed data
with log-link technique was selected. Literature
comparing GLMs for use in health economic analysis
suggests the gamma log-link model as a candidate
to provide a good fit for health care cost data, given
its tendency for skewness, excess zeros and heavy
right tails.8-11 The final statistical model was selected
after a comprehensive assessment of study data as
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Table 1. Description of Study Variables
Variable

Behavioral model type

Measurement or range

WHIO DataMart

Leukemia diagnosis cost:
ICD-9 code 204.xx
ICD-9 code 205.xx

Criterion variable

Total
Inpatient
Outpatient
Pharmaceutical
Ancillary
Professional

Cost = billed
Cost = standard
Service type:
Ancillary = 1
Inpatient = 2
Outpatient = 3
Professional = 4
P
 harmacy = 7 (does not
include retail pharmacy claims)

Age

Predisposing
characteristic

1–90 years

Age

Gender

Predisposing
characteristic

0 = male
1 = female

Gender

Length of follow-up

Predisposing
characteristic

1–25 months

End date of service to start date
of service

Episode severity level

Need characteristic

1 = low
2 = low/medium
3 = high/medium
4 = high

Severity = highest level of
severity coded

Treatment type

Need characteristic

0 = chemotherapy only
1 = chemotherapy and HCT

ICD code

Patient ZIP code; % of
county below poverty level

Enabling resources

ZIP: 5-digit character; County
poverty: continuous ratio

ZIP code; U.S. Census for %
of all people below poverty level

Payer type

Enabling resources

0 = commercial
1 = public

Payer type = public payer coded
when present

Provider type

Enabling resources

0 = community
1 = academic

Provider name

Provider ZIP code; % of
ZIP below poverty level

Enabling resources

ZIP: 5 digit character;
Provider ZIP poverty: %

ZIP code; U.S. Census for %
of all people below poverty level

HCT, hematopoietic stem cell transplant.

well as for its ability to accommodate right-skewed
data, the presence of zeros, differences in follow-up,
many low-cost events versus few high-cost events,
and overall fit considering model assumptions. The
modified Park’s test identified both Poisson and
gamma family distributions as appropriate, given
the cost criterion assessed, and visual inspection of
residuals associated with raw and log-transformed
data supported use of the log-link for approximating
a normal distribution.
Modeling techniques used in this study ultimately
produced estimates of predictor variable effect
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size (eβ), quantifying the magnitude of change
in mean criterion value per 1-unit change in the
predictor variable and offering the advantage of
easier comparison and interpretation of differences
between groups.12-14 Each cost criterion variable was
modeled to determine: 1) if a patient’s predisposing
characteristics (i.e. age, gender and length of followup), need for service factors (i.e. treatment type
and episode severity), and enabling patient and
community resources (i.e. percentage of residents in
patient’s county in poverty, payer type, provider type
and percentage of residents in provider location in
poverty) were predictive of cost; and 2) the magnitude
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of predictor variable influence on cost criterion
variables. To identify variables that significantly
influenced cost, each cost criterion was initially
analyzed in a full model using all study variables.
Table 2 provides the description of the final GLM
gamma log-link models.
Variables for analysis in reduced models were
identified in the GLM using a chi-squared test of the
likelihood ratio with α of 0.05. Finally, a two-step
hierarchical model was used to assess the influence
of patient and community enabling variables over
and above the influence of a patient’s predisposing
characteristics and need for services. This model
began with the predisposing and need variables, then
added the patient and community enabling variables.

RESULTS

Descriptive information of standard cost for each
criterion variable is shown in Table 3. Mean standard
cost varies greatly between criterion variables, for
which inpatient costs were highest and ancillary
costs lowest. Large differences were noted between
mean and median cost, however, both follow similar
direction.
Each significant full-model predictor variable also
was significant in the reduced model. Only total cost
was analyzed in the hierarchical model, and the results
were the same as those of the reduced model. Reduced
model results are presented as mean ratios and used a
coefficient of variation, which represents the ratio of
differences between groups as eβ (Table 4).

Table 2. Final GLM Gamma Log-Link Models
Variable
1. E(Y
 Totalcost) = exp(β0 + β1lengthoffollow-up + β2age + β3gender + β4treatmenttype + β5severity + β6county%belowpoverty
+ β7payertype + β8providertype + β9provider%belowpoverty)
2. E(YAncillarycost) = exp(β + β lengthoffollow-up + β age + β gender + β treatmenttype + β severity +
0
1
2
3
4
5
β6county%belowpoverty + β7payertype + β8providertype + β9provider%belowpoverty)
3. E
 (YInpatientcost) = exp(β + β lengthoffollow-up + β age + β gender + β treatmenttype + β severity +
0
1
2
3
4
5
β6county%belowpoverty + β7payertype + β8providertype + β9provider%belowpoverty)
4. E
 (YOutpatientcost) = exp(β + β lengthoffollow-up + β age + β gender + β treatmenttype + β severity +
0
1
2
3
4
5
β6county%belowpoverty + β7payertype + β8providertype + β9provider%belowpoverty)
5. E
 (YPharmacycost) = exp(β + β lengthoffollow-up + β age + β gender + β treatmenttype + β severity +
0
1
2
3
4
5
β6county%belowpoverty + β7payertype + β8providertype + β9provider%belowpoverty)
6. E(YProfessionalcost) = exp(β + β lengthoffollow-up + β age + β gender + β treatmenttype + β severity +
0
1
2
3
4
5
β6county%belowpoverty + β7payertype + β8providertype + β9provider%belowpoverty)

Table 3. Description of Standard Costs
Cost criterion
Total cost
Ancillary
Inpatient
Outpatient
Pharmacy
Professional
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N

Mean

Median

Standard
deviation

Range

25%
quartile

75%
quartile

837
164
232
639
390
748

43,379
4,123
80,787
8,410
17,078
6,491

2,723
1,230
40,908
1,953
5,070
1,002

102,703
8,834
104,001
17,590
60,012
11,379

10–1,228,960
5–64,248
2,680–836,656
10–227,957
1–1,097,437
7–80,867

539
296
16,855
493
483
298

35,471
3,248
107,750
9208
17,434
7,448
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Table 4. Estimated Reduced Model Summary Results for Standard Cost
Predisposing
characteristics*

Reduced model standard claims cost
Total

Ancillary

Inpatient

Outpatient

Pharmacy

Professional

Age (decade)
eβ
95% CI
P-value

0.92
0.87–0.96
0.007

0.98
0.97–1.002
0.08

0.88
0.83–0.93
<0.0001

0.92
0.88–0.97
0.002

1.15
1.07–1.23
<0.0001

0.88
0.84–0.91
<0.0001

Gender
eβ
95% CI
P-value

1.66
1.28–2.15
0.0001

Length of follow-up
(months)
eβ
95% CI
P-value

1.03
1.003–1.05
<0.0001

Need
characteristics*

Total

1.3
1.04–1.64
0.02

Ancillary

0.98
0.96–1
0.05

1.06
1.04–1.07
<0.0001

1.03
1.05–0.03
0.02

1.08
1.07–1.09
<0.0001

Inpatient

Outpatient

Pharmacy

Professional

0.3
0.2–0.45
<0.0001

0.19
0.12–0.32
<0.0001

Treatment type
eβ
95% CI
P-value

0.14
0.06–0.26
<0.0001

Severity level 1
eβ
95% CI
P-value

0.41
0.26–0.61
0.0002

0.24
0.07–0.95
0.02

0.28
0.17–0.49
<0.0001

0.32
0.20–0.51
<0.0001

0.34
0.17–0.67
0.002

0.47
0.34–0.67
<0.0001

Severity level 2
eβ
95% CI
P-value

0.45
0.34–0.61
<0.0001

0.35
0.19–0.66
0.001

0.55
0.41–0.74
<0.0001

0.47
0.34–0.66
<0.0001

0.6
0.39–0.93
0.02

0.51
0.41–0.63
<0.0001

0.64
0.44–0.92
0.02

0.59
0.35–0.96
0.03

Severity level 3
eβ
95% CI
P-value
Enabling
resources*
Provider type
eβ
95% CI
P-value

0.32
0.17–0.61
0.0004

0.22
0.12–0.36
<0.0001

Total

Ancillary

Inpatient

Outpatient

Pharmacy

0.71
0.54–0.94
0.018

0.46
0.26–0.79
0.005

0.73
0.55–0.95
0.02

0.56
0.43–0.71
<0.0001

0.62
0.44–0.89
0.01

0.97
0.96–0.99
<0.0001

0.95
0.93–0.98
0.002

Provider % under
poverty
eβ
95% CI
P-value

Professional

*Determinants in Andersen’s model of health care utilization.
CI, confidence interval; eβ, estimates of predictor variable effect size.
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Total Cost
The average total cost for males was more than one
and a half times the average total cost for females,
and each additional month that a patient had claims
present increased the average total cost by close to
2%. The average total cost of patients treated with
only chemotherapy was 86% lower than the average
total cost with both chemotherapy and HCT treatment.
Patients with low illness severity (level 1) had a 59%
lower average total cost than higher severity levels;
patients with low- to mid-range severity (level 2)
had a 55% less average total cost than higher levels
of severity (3 and 4). Community provider’s average
total costs were 29% lower than average total costs of
academic providers, and patients average total cost was
8% lower for every 10-year increase in patient age.
Ancillary Cost
The average ancillary cost of patients with low illness
severity (level 1) was 76% lower than the average
ancillary cost of patients with high severity level 4,
patients with mid-range severity levels (levels 2 and
3) had 66% and 68% lower average ancillary costs
than patients with high severity (level 4). Community
provider average ancillary costs were 54% lower than
the average ancillary cost of academic providers.
Inpatient Cost
The average inpatient cost of patients treated with only
chemotherapy was 70% lower than the average inpatient
cost of both chemotherapy and HCT treatment. Patients
with low illness severity (level 1) had a 72% lower
average inpatient cost than patients with high severity
(level 4), and patients with mid-range severity (level 2)
had a 45% lower average inpatient standard cost than
those with high severity (level 4). Community providers
had 27% lower average inpatient cost than academic
providers. Average inpatient cost was reduced by 12%
for every 10-year increase in patient age, and each
additional month that a patient had claims increased the
average inpatient cost by close to 2%.
Outpatient Cost
Males had 30% higher average outpatient cost
compared to females, and each additional month that
claims were present increased average outpatient cost
by 5.5%. For each 10-year increase in age, average
outpatient cost decreased by 7.6%. Patients treated
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with only chemotherapy had an 81% lower average
outpatient cost than patients treated with both
chemotherapy and HCT. Patients with low illness
severity (level 1) had a 68% lower average outpatient
cost than patients with high severity (level 4), patients
with mid-range severity (level 2 or 3) had a 53% and
36% lower average outpatient cost, respectively,
than those with high severity (level 4). Community
providers had a 44% lower average outpatient cost
than academic providers, and every 1% increase in
the rate of poverty at the provider’s location reduced
average outpatient cost by 3%.
Pharmacy Cost
For each 10-year increase in patient age, average
pharmacy cost decreased by 15%. Each additional
month that claims were present increased average
pharmacy cost by 3%. Patients with low illness
severity (level 1) had a 66% lower average pharmacy
cost than patients with high severity (level 4); patients
with mid-range severity (level 2 or 3) had a 40% and
41% lower average pharmacy cost, respectively, than
those with high severity (level 4). Cost for community
providers was 38% lower than the average pharmacy
cost of an academic provider, and every 1% increase
in the provider location poverty rate reduced average
pharmacy cost by 5%.
Professional Cost
Each additional month that a patient had claims
present increased average professional cost by close
to 8%. For each 10-year increase in age, average
professional cost decreased by 12.5%. Patients
treated with only chemotherapy had a 78% lower
average professional cost than those treated with
both chemotherapy and HCT. Patients with low
illness severity (level 1) had a 53% lower average
professional cost than patients with high severity
(level 4), and patients with mid-range severity (level
2) had a 49% lower average professional cost than
high-severity patients (level 4).

DISCUSSION

The objective of this study was to identify and better
understand factors associated with use of health
services specific to patients diagnosed with acute
myeloid leukemia and acute lymphoblastic leukemia.
The overall health care cost burden of a patient is
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determined by the type of service received, where it
was received, who provided it and its duration. This
study investigated ancillary, inpatient, outpatient,
pharmacy and professional costs in addition to
total cost in an attempt to distinguish how the cost
of each type of service impacts the total cost to the
patient. Acute leukemia patient characteristics of the
study population were consistent with those reported
nationally.15 Patient characteristics were consistent
between each criterion, with a mean age of either 27
or 28 and a higher percentage of males, as would be
expected from the higher rate of leukemia diagnoses
in males. Such demographics are similar to national
Surveillance, Epidemiology, and End Results (SEER)
statistics, which report a higher percentage of men
with acute leukemia diagnoses as well as both a
younger acute lymphoblastic leukemia population
and an older acute myeloid leukemia population.15
Our study found certain patient characteristics to
be predictive of cost; however, it also revealed that
health care costs of rare disease populations may
not follow cost patterns for more common disease.
Prior research identifies increasing age as a factor
associated with higher health care utilization rates
and costs.16 This study found that the younger age of
an acute leukemia patient is associated significantly
with higher average cost. Bertakis et al. identified a
gender difference in the use of health care services,
with a higher rate of use in women.17 However, in this
study population, men had higher costs. Billings et al.
found higher rates of hospitalization in low-income
areas attributed to less timely and effective outpatient
care.18 For certain cost variables in our study the
opposite was found, in that inpatient cost was lower
in low-income areas.
Other study results were consistent with more typical
health care cost patterns. Zweifel et al. reported cost
of treatment to be an important driver of total cost,19
similar to our study’s findings. Patients receiving
treatment with HCT experienced significantly higher
cost when compared to those treated only with
chemotherapy. This finding is consistent with the
identification of HCT as the procedure with the most
rapidly increasing cost between 2004 and 2007.20
Advances in scientific knowledge have expanded HCT
treatment to a variety of hematologic diseases and
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disorders; however, its high cost makes it vulnerable
to cost containment. As expected, patients with
higher severity of illness had higher cost associated
with an increased need for health care services. In
the Andersen model, socioeconomics is considered a
factor that may impact how patients use health care
services, with higher socioeconomic status supporting
higher utilization.5 Findings of this study support the
theory of lower costs associated with lower utilization
and lower socioeconomic status. Finally, the direction
of study findings were not consistent between the
different types of services received and underscore
the complexity of understanding the factors that drive
the total cost outcome.
Study Limitations
The study’s research design was restricted because
of the limitations of data available in the WHIO
administrative claims database. Data censoring due
to death and changes in patient insurance influence
the amount of follow-up claims data available, and
such causes were not delineated in the database.
The study population was defined by a subset of
Wisconsin insurance claims and did not include
patients who did not pay with insurance or used
insurance administered from a different U.S. state.
Patient ZIP code was available at the county level
only, and its specificity was reduced. Assessment
of interactions was outside the scope of the analysis
due to the number of potential combinations. Finally,
analysis of cost data was complex due to its tendency
to be skewed, with long, right tails, multiple zero
values and large differences in rates of health services
utilization causing a higher proportion of heath care
cost to be attributed to a smaller group of patients,
and a non-normal distribution of data.

CONCLUSIONS

Health care costs of less common diseases such as
acute leukemia may not follow patient characteristic
patterns found in more common disease populations.
Using Andersen’s behavioral model of health care
utilization, study variables were identified that
represent patient and community factors expected to
influence cost. Based on a generalized linear model
fitting gamma-distributed data with log-link technique,
individual and community factors were found to be
significant predictors within each cost criterion and
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provide opportunities for further investigation of
higher costs at the patient, provider and community
levels. Assessing the unique influence of each variable
on each cost outcome as well as further exploration
into types of treatment offered by providers in different
socioeconomic locations is advisable.
Patient-Friendly Recap
• Health care costs for patients with leukemia are
substantial.
• The authors reviewed statewide data to
determine which patient, provider and
community factors drive up total cost.
• They found that type of treatment received and
disease severity were the biggest contributors to
higher cost, but also observed a jump in patients
receiving at least some of their treatment from an
academic medical center.
• Inpatient and pharmacy costs were lower when
providers were located in impoverished areas,
raising the possibility of treatment disparities.
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